You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Demographics and clinical characteristics of the intent to treat study population stratified by ciprofloxacin susceptibility status

From: Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial

  Ciprofloxacin-susceptible N = 430 (84.3%) Ciprofloxacin-resistant N = 80 (15.7%) All N = 510 P value
Demographics
 Age, mean +/− SD, (range), years 62.7 ± 9.1 (33–88) 61.6 ± 7.6 (42–77) 62.5 ± 8.9 (33–88) 0.323
 Race, n (%)     0.101
  White 324 (75.3) 52 (65.0) 376 (73.7)  
  Black 68 (15.8) 15 (18.8) 83 (16.3)  
  Hispanic 21 (4.9) 9 (11.2) 30 (5.9)  
  Other 17 (4.0) 4 (5.0) 21 (4.1)  
Clinical characteristics
 Reason for biopsy, n (%)     0.745
  Elevated PSA 357 (83.0) 66 (82.5) 423 (82.9)  
  Abnormal DRE 29 (6.7) 4 (5.0) 33 (6.5)  
  Both 27 (6.3) 5 (6.2) 32 (6.3)  
  Other 17 (4.0) 5 (6.2) 22 (4.3)  
 Biopsy result, n (%)     0.848
  Negative 219 (50.9) 38 (47.5) 257 (50.4)  
  Prostate cancer 167 (38.8) 34 (42.5) 201 (39.4)  
  HGPIN 44 (10.2) 8 (10.0) 52 (10.2)  
 History of urinary tract infection, n (%)     0.004
  Yes 39 (9.1) 16 (20.0) 55 (10.8)  
  No 382 (88.8) 60 (75.0) 442 (86.7)  
  Unknown/missing 9 (2.1) 4 (5.0) 13 (2.5)  
 History of urinary retention; n (%)     0.769
  Yes 33 (7.7) 6 (7.5) 39 (7.6)  
  No 354 (82.3) 64 (80.0) 418 (82.0)  
  Unknown/missing 43 (10.0) 10 (12.5) 53 (10.4)  
 FQ usage in prior 2 years, n (%)     0.921
  Yes 95 (22.1) 19 (23.8) 114 (22.3)  
  No 225 (52.3) 42 (52.5) 267 (52.4)  
  Unknown/missing 110 (25.6) 19 (23.8) 129 (25.3)  
 Hospitalized in prior 1 year; n (%)     0.653
  Yes 42 (9.8) 6 (7.5) 48 (9.4)  
  No 374 (87.0) 73 (91.2) 447 (87.7)  
  Unknown/missing 14 (3.3) 1 (1.2) 15 (2.9)  
 Healthcare worker; n (%)     0.728
  Yes 14 (3.3) 2 (2.5) 16 (3.1)  
  No 357 (83.0) 70 (87.5) 427 (83.7)  
  Unknown/missing 59 (13.7) 8 (10.0) 67 (13.1)  
 Charlson comorbidity score; n (%)     0.693
  0 348 (80.9) 68 (85.0) 416 (81.6)  
  1 16 (3.7) 2 (2.5) 18 (3.5)  
  2 32 (7.4) 3 (3.8) 35 (6.9)  
  3–16 34 (7.9) 7 (8.8) 41 (8.0)  
  1. Abbreviations: PSA prostate-specific antigen, DRE digital rectal exam, HGPIN high-grade prostatic intraepithelial neoplasia, FQ fluoroquinolone